Evidence map›Paper›PMID 27578884›Full record

ArticleProtein engineering, design & selection : PEDS2016

A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.

Tim D Jones, Arron R Hearn, Robert G E Holgate, Dorota Kozub, Mark H Fogg, Francis J Carr, Matthew P Baker, Javier Lacadena, Kurt R Gehlsen

Open access · hybridAbstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Tim D JonesAbzena plc., Babraham Research Campus, Babraham, CambridgeCB22 3AT, UK.
Arron R HearnAbzena plc., Babraham Research Campus, Babraham, CambridgeCB22 3AT, UK.
Robert G E HolgateAbzena plc., Babraham Research Campus, Babraham, CambridgeCB22 3AT, UK.
Dorota KozubAbzena plc., Babraham Research Campus, Babraham, CambridgeCB22 3AT, UK.
Mark H FoggAbzena plc., Babraham Research Campus, Babraham, CambridgeCB22 3AT, UK.
Francis J CarrAbtelum Biomedical, Inc. 175 Briar Lane, Westwood, MA 02090, USA.
Matthew P BakerAbzena plc., Babraham Research Campus, Babraham, CambridgeCB22 3AT, UK.
Javier LacadenaDepartamento de Bioquimica y Biologia Molecular I, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Avenida Complutense s/n, Madrid 28040, Spain.
Kurt R GehlsenResearch Corporation Technologies Inc., 5210 E. Williams Circle #240, Tucson, AZ 85711, USA.
Abzena (United Kingdom) · GBUniversidad Complutense de Madrid · ESWilliams (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungal ribotoxins that block protein synthesis can be useful warheads in the context of a targeted immunotoxin. α-Sarcin is a small (17 kDa) fungal ribonuclease produced by Aspergillus giganteus that functions by catalytically cleaving a single phosphodiester bond in the sarcin-ricin loop of the large ribosomal subunit, thus making the ribosome unrecognisable to elongation factors and leading to inhibition of protein synthesis. Peptide mapping using an ex vivo human T cell assay determined that α-sarcin contained two T cell epitopes; one in the N-terminal 20 amino acids and the other in the C-terminal 20 amino acids. Various mutations were tested individually within each epitope and then in combination to isolate deimmunised α-sarcin variants that had the desired properties of silencing T cell epitopes and retention of the ability to inhibit protein synthesis (equivalent to wild-type, WT α-sarcin). A deimmunised variant (D9T/Q142T) demonstrated a complete lack of T cell activation in in vitro whole protein human T cell assays using peripheral blood mononuclear cells from donors with diverse HLA allotypes. Generation of an immunotoxin by fusion of the D9T/Q142T variant to a single-chain Fv targeting Her2 demonstrated potent cell killing equivalent to a fusion protein comprising the WT α-sarcin. These results represent the first fungal ribotoxin to be deimmunised with the potential to construct a new generation of deimmunised immunotoxin therapeutics.

Indexed as

deimmunisationimmunogenicityimmunotoxinT cell epitopeα-sarcin

Identifiers

PMID27578884
PMCPMC5081043
OpenAlexW2510300927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.